JJ as I scrolled through the CTAD sessions hoping to see Anavex I was perplexed at all the desperate angles companies (this isnt even close to what else is out there) are striving to show even but a glimpse of efficacy after weighing all the bad side affects of their drugs. I say desperate because some are on the cusp of make or break financially.
Then like you said, Anavex is a no show, at least not yet, which is bizarre historically. Couple that with our last minute receiveing of data and last minute entry. Things that make you go hmmmm.
Well, this led me to think, if I was a small company, who had a pretty good war chest, and was sitting (possibly) on the next SOC (after analyzing my data very thoroughly with our new guy), why would I want the distraction of CTAD, especially during heavy negotiations. Negotiations that would/could possibly tie up data release for Rett and AD. Negotiations that when fully disclosed complete the circle and upon Fda approval (Rett pending?) leave absolutely no doubt about efficacy. This is the real news, the real CTAD, all the rest are just looking to apply a thin coat of lipstick to their trials so they can garner further investment from the HF’s. Look no further than biogen sucking the air out of the room with its many desperate attempts to BS the world into paying for their failed death delivering drugs.
Im still patient until the end of the year.
Wha
News 
Market Data 
Discover 
